Menveo Beats Menactra In Teen Meningitis Phase III Trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis' Menveo meningitis vaccine was more effective against four meningococcal serogroups in patients ages 11 to 18 than Sanofi-Aventis' Menactra, in a Phase III clinical trial